Text Size

Pfizer CEO Jeffrey Kindler Honored with Catalyst Award

Jeffrey B. Kindler received the 2010 Catalyst Award, the Glaucoma Research Foundation’s highest honor, acknowledging his exemplary leadership in sustaining innovative research and education.

Mr. Kindler is Chief Executive Officer and Chairman of the Board of Pfizer Inc., the world’s largest research-based pharmaceutical company. Mr. Kindler leads a worldwide company dedicated to improving human health and preventing vision loss from blinding eye diseases.

The Award was presented during the Glaucoma Research Foundation Annual Benefit celebration on Wednesday evening at The Palace Hotel. Accepting the award on behalf of Kindler was Michael Berelowitz, MB ChB, FACP, FCP, Senior Vice President, Clinical Development & Medical Affairs, Specialty Care Business Unit for Pfizer Inc. A native of South Africa whose research interest is Diabetes, Dr. Berelowitz was a professor of endocrinology and metabolism before joining Pfizer in 1996.

Last year’s Catalyst Award recipient, H. Dunbar Hoskins, Jr., MD, former Executive Vice President of the American Academy of Ophthalmology and a founder of the Glaucoma Research Foundation, presented the 2010 Catalyst Award. In his comments, Dr. Hoskins praised Kindler’s leadership in vision research and ophthalmology. “Pfizer makes the leading glaucoma medication, Xalatan, and has been committed to supporting ophthalmic research and patient education for many years,” Hoskins said. “Pfizer has long been a generous supporter of Glaucoma Research Foundation’s research and educational programs.”

All previous recipients of the Catalyst Award were present at the evening’s ceremonies, including Steven Kirsch; Allergan Chairman, President and CEO David E. I. Pyott; GRF board member F.T. Barr; and Alcon Chairman, and Former President and CEO Cary Rayment, all of whom have demonstrated exemplary leadership in their commitment to innovative research.

Last reviewed on March 07, 2011

Was this helpful? Yes No